Pulmonary Embolism occurs when blood clots travel to the lung and block one or more arteries. The clots prevent that area of the lung from doing its job of oxygenating the bloodstream. It is a serious disease, which can lead to death. Pulmonary Embolism (PE) is also a frequent serious complication of COVID-19. Almost half the COVID-19 patients hospitalized in the ICU suffer from PE, which often turns fatal.
The currently approved treatment of administering systemic thrombolytic drugs to break up the clots can cause unwanted bleeding in other places. Because of this risk, only the most severe cases are treated this way. More invasive options are available, but they also carry a relatively high risk and are expensive.
NewMed’s patent pending treatment for Pulmonary Embolism, Localysis™, uses a simple, non-invasive bedside procedure to deliver life-saving thrombolytic drugs directly to the pulmonary arterial tree. It significantly reduces the risk of bleeding elsewhere in the body, and makes thrombolytic therapy available to most patients suffering from pulmonary embolism.
Localysis™ reduces morbidity and mortality, reduces the cost of treatment and brings significant savings to the health system.
